Literature DB >> 30911933

Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress.

Michael Maes1,2,3,4, Juliana Brum Moraes5, Ana Congio5, Kamila Landucci Bonifacio5, Decio Sabbatini Barbosa5, Heber Odebrecht Vargas5, Ana Paula Michelin5, Andre F Carvalho6,7, Sandra Odebrecht Vargas Nunes5.   

Abstract

Although, staging models gained momentum to stage define affective disorders, no attempts were made to construct mathematical staging models using clinical and biomarker data in patients with major depression and bipolar disorder. The aims of this study were to use clinical and biomarker data to construct statistically derived staging models, which are associated with early lifetime traumata (ELTs), affective phenomenology, and biomarkers. In the current study, 172 subjects participated, 105 with affective disorders (both bipolar and unipolar) and 67 controls. Staging scores were computed by extracting latent vectors (LVs) from clinical data including ELTs, recurring flare ups and suicidal behaviors, outcome data such as disabilities and health-related quality of life (HR-QoL), and paraoxonase (PON)1 actvities and nitro-oxidative stress biomarkers. Recurrence of episodes and suicidal behaviors could reliably be combined into a LV with adequate composite reliability (the "recurrence LV"), which was associated with female sex, the combined effects of multiple ELTs, disabilities, HR-QoL, and impairments in cognitive tests. All those factors could be combined into a reliable "ELT-staging LV" which was significantly associated with nitro-oxidative stress biomarkers. A reliable LV could be extracted from serum PON1 activities, recurrent flare ups, disabilities, and HR-QoL. Our ELT-staging index scores the severity of a relevant affective dimension, shared by both major depression and bipolar disorder, namely the trajectory from ELTs, a relapsing course, and suicidal behaviors to progressive disabilities. Patients were classified into three stages, namely an early stage, a relapse-regression stage, and a suicidal-regression stage. Lowered lipid-associated antioxidant defenses may be a drug target to prevent the transition from the early to the later regression stages.

Entities:  

Keywords:  Affective disorders; Bipolar disorder; Major depression; Neuro-immune; Oxidative; Staging

Mesh:

Substances:

Year:  2019        PMID: 30911933     DOI: 10.1007/s12035-019-1552-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  13 in total

1.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach.

Authors:  Michael Maes; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

2.  Development of a Novel Neuro-immune and Opioid-Associated Fingerprint with a Cross-Validated Ability to Identify and Authenticate Unknown Patients with Major Depression: Far Beyond Differentiation, Discrimination, and Classification.

Authors:  Hussein Kadhem Al-Hakeim; Suhaer Zeki Al-Fadhel; Arafat Hussein Al-Dujaili; Andre Carvalho; Sira Sriswasdi; Michael Maes
Journal:  Mol Neurobiol       Date:  2019-05-23       Impact factor: 5.590

3.  Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present.

Authors:  Denitsa Simeonova; Drozdstoy Stoyanov; Jean-Claude Leunis; Andre F Carvalho; Marta Kubera; Marianna Murdjeva; Michael Maes
Journal:  Neurotox Res       Date:  2019-12-04       Impact factor: 3.911

Review 4.  False dogmas in mood disorders research: Towards a nomothetic network approach.

Authors:  Michael Hj Maes; Drozdstoy Stoyanov
Journal:  World J Psychiatry       Date:  2022-05-19

5.  Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels.

Authors:  Michael Maes; Joao Victor Nani; Cristiano Noto; Lucas Rizzo; Mirian A F Hayashi; Elisa Brietzke
Journal:  Mol Neurobiol       Date:  2020-09-11       Impact factor: 5.590

Review 6.  How to construct neuroscience-informed psychiatric classification? Towards nomothetic networks psychiatry.

Authors:  Drozdstoy Stoyanov; Michael Hj Maes
Journal:  World J Psychiatry       Date:  2021-01-19

7.  Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis.

Authors:  Ana Paula Michelin; Michael H J Maes; Thitiporn Supasitthumrong; Chusak Limotai; Andressa Keiko Matsumoto; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefânia Gastaldello Moreira; Buranee Kanchanatawan; Décio Sabbatini Barbosa
Journal:  World J Psychiatry       Date:  2022-02-19

8.  The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.

Authors:  Michael Maes; Muanpetch Rachayon; Ketsupar Jirakran; Pimpayao Sodsai; Siriwan Klinchanhom; Piotr Gałecki; Atapol Sughondhabirom; Agnieszka Basta-Kaim
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

9.  Increased C-reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and meta-analysis.

Authors:  Alessandro Miola; Veronica Dal Porto; Tal Tadmor; Giovanni Croatto; Paolo Scocco; Mirko Manchia; Andre F Carvalho; Michael Maes; Eduard Vieta; Fabio Sambataro; Marco Solmi
Journal:  Acta Psychiatr Scand       Date:  2021-08-25       Impact factor: 7.734

10.  Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self.

Authors:  Michael Maes
Journal:  J Pers Med       Date:  2022-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.